ReviewTheScientificWorldJournal2013
Dendrimeric systems and their applications in ocular drug delivery.
Review in TheScientificWorldJournal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 105 citations in OpenAlex.
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Dendrimers-based Hydrogels and Nanogels for Drug Delivery.Current pharmaceutical biotechnology · 2026Review
- Nanotechnology-Based Delivery Systems and Retinal Pigment Epithelium: Advances, Targeting Approaches, and Translational Challenges.Biomolecules · 2025Review
- COThe journal of physical chemistry. B · 2025Article
- Biodegradable Contact Lenses for Targeted Ocular Drug Delivery: Recent Advances, Clinical Applications, and Translational Perspectives.Molecules (Basel, Switzerland) · 2025Review
- Localization of fluorescent gold nanoparticles throughout the eye after topical administration.Frontiers in medicine · 2025Article
- Light-responsive polymeric nanoparticles for retinal drug delivery: design cues, challenges and future perspectives.Heliyon · 2024Review
- Seeing the Future: A Review of Ocular Therapy.Bioengineering (Basel, Switzerland) · 2024Review
- Review
- Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases.Pharmaceutics · 2023Review
- Therapeutic effect of ultra-long-lasting human C-peptide delivery against hyperglycemia-induced neovascularization in diabetic retinopathy.Theranostics · 2023Article
- Parametric Drug Release Optimization of Anti-Inflammatory Drugs by Gold Nanoparticles for Topically Applied Ocular Therapy.International journal of molecular sciences · 2022Article
- Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies.International journal of pharmaceutics · 2021Review
- Molecular Modelling Guided Modulation of Molecular Shape and Charge for Design of Smart Self-Assembled Polymeric Drug Transporters.Pharmaceutics · 2021Review
- Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery.Nanomaterials (Basel, Switzerland) · 2021Review
- Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective.International journal of nanomedicine · 2021Review
- Considerations for Polymers Used in Ocular Drug Delivery.Frontiers in medicine · 2021Review
- Dendrimers and Dendritic Materials: From Laboratory to Medical Practice in Infectious Diseases.Pharmaceutics · 2020Review
- Dendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications.Materials (Basel, Switzerland) · 2019Review
- Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents.Pharmaceutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ophthalmic drug delivery is one of the most attractive and challenging research area for pharmaceutical scientists and ophthalmologists. Absorption of an ophthalmic drug in conventional dosage forms is seriously limited by physiological conditions. The use of nonionic or ionic biodegradable polymers in aqueous solutions and colloidal dosage forms such as liposomes, nanoparticles, nanocapsules, microspheres, microcapsules, microemulsions, and dendrimers has been studied to overcome the problems mentioned above. Dendrimers are a new class of polymeric materials. The unique nanostructured architecture of dendrimers has been studied to examine their role in delivery of therapeutics and imaging agents. Dendrimers can enhance drug's water solubility, bioavailability, and biocompatibility and can be applied for different routes of drug administration successfully. Permeability enhancer properties of dendrimers were also reported. The use of dendrimers can also reduce toxicity versus activity and following an appropriate application route they allow the delivery of the drug to the targeted site and provide desired pharmacokinetic parameters. Therefore, dendrimeric drug delivery systems are of interest in ocular drug delivery. In this review, the limitations related to eye's unique structure, the advantages of dendrimers, and the potential applications of dendrimeric systems to ophthalmology including imaging, drug, peptide, and gene delivery will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.